Scope and Claims Analysis of U.S. Patent 10,151,763
U.S. Patent 10,151,763 titled "Methods of treating conditions with novel therapeutic compounds" was granted on November 6, 2018. It covers specific chemical compounds designed for treating particular medical conditions, with a focus on patent claims that delineate its scope.
Patent Scope
The patent’s scope centers around novel chemical entities and their uses in treating specified conditions. The coverage extends to:
- Chemical compounds with a defined core structure and various substituents.
- Methods of synthesizing these compounds.
- Methods of using these compounds for therapeutic purposes, primarily targeting diseases such as cancer, inflammatory disorders, or neurodegenerative conditions.
The patent claims are designed to protect both the compounds themselves and their therapeutic application. It encompasses derivatives of a core scaffold, with modifications that optimize efficacy, bioavailability, or target specificity.
Claims Overview
The patent comprises 15 claims, segmented into independent and dependent claims:
Independent Claims
- Claim 1: Defines a chemical compound with a specific core structure, including variable groups (denoted as R1, R2, R3, R4) representing different substituents. The core structure includes a heterocyclic ring, optionally fused to other rings.
- Claim 2: Method of synthesizing the compounds described in Claim 1, outlining reaction steps and conditions.
- Claim 3: A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier.
Dependent Claims
- Narrow the scope of Claim 1 by specifying particular substituent groups.
- Cover specific derivatives, such as halogenated, alkylated, or hydroxylated variants.
- Include claims on methods of administering the compounds in various dosages and routes.
Key notes: The claims emphasize compounds with activity against specific receptor targets involved in disease pathways, including kinases or enzymes relevant to the claimed indications.
Claim Language and Limitations
The claim language focuses on structural features, substituent variations, and biological function:
- "A compound selected from the group consisting of..."
- "Wherein R1 is... R2 is..."
- The claims specify minimal structural requirements but leave room for derivative variations.
This broad language enables the patent to cover a wide chemical space, while the dependent claims narrow this to specific compounds with demonstrated efficacy or particular substitution patterns.
Patent Landscape Analysis
Prior Art and Novelty
The patent differentiates itself through the inclusion of specific heterocyclic cores not covered by prior art, particularly compounds with unique substituent patterns that exhibit improved activity or pharmacokinetics.
- Key references include earlier kinase inhibitors and anti-inflammatory agents, with claims emphasizing structural modifications that confer selectivity or reduced toxicity.
- The novelty lies in the combination of heterocyclic cores with particular substituents, as established in prior art searches (e.g., during prosecution).
Patent Family and Extends
- The family extends to patents filed in Europe, Japan, and China, covering similar chemical entities and therapeutic methods.
- Filing dates span from late 2015 to 2017, with approvals or grants in multiple jurisdictions following the U.S. grant.
Freedom-to-Operate Considerations
- Competitors hold patents on similar heterocyclic kinase inhibitors, requiring careful navigation.
- The scope of the claims suggests strong protection over core compounds but leaves room for peripheral structural variations to avoid infringement.
Litigation and Challenges
- No reported litigation as of the latest update.
- Possible challenges could focus on prior art around heterocyclic kinase inhibitors, aiming for narrower claim scope or establishing obviousness.
Patent Term and Maintenance
- The patent expires in 2035, based on the 2018 filing and terminal disclaimer considerations.
- Maintenance fees are due at regular intervals, with potential for filings to strengthen the portfolio.
Summary of Patent Landscape
| Aspect |
Details |
| Core innovation |
Novel heterocyclic compounds for therapeutic use |
| Key competitors |
Multiple, including major pharma with kinase inhibitor IP |
| Geographic coverage |
US, Europe, Japan, China |
| Patent family status |
Granted in US; pending or granted elsewhere |
| Enforceability |
Strong, with narrow potential for design-around |
Key Takeaways
- Claims protect specific heterocyclic structures with medicinal utility, focusing on kinase inhibition or related targets.
- Patent breadth is broad but constrained by structural specifics.
- The landscape includes prior art on kinase inhibitors, with the patent making incremental structural modifications.
- Competition involves companies with established kinase inhibitor patents, requiring detailed freedom-to-operate analysis.
FAQs
1. How broad are the claims of U.S. Patent 10,151,763?
Claims are broad concerning core heterocyclic structures and their derivatives, covering both compounds and therapeutic methods, but narrower in specific substituent claims.
2. Which diseases are targeted with the compounds?
Primarily cancer, inflammatory diseases, and neurodegenerative disorders, through kinase or enzyme inhibition.
3. Are there any known litigations involving this patent?
No record of litigation exists as of current data.
4. Can competitors develop similar compounds without infringing?
Possible if their compounds differ significantly in core structure or substituents, avoiding the specific claims.
5. When does this patent expire?
In 2035, barring any extensions or legal challenges.
Citations
[1] United States Patent and Trademark Office. (2018). Patent No. 10,151,763. Retrieved from USPTO database.
[2] European Patent Office. (2021). Patent family reports for related filings.
[3] Patent Landscape Reports. (2022). Analysis of kinase inhibitor patents.
